54
Participants
Start Date
February 13, 2025
Primary Completion Date
September 26, 2025
Study Completion Date
September 26, 2026
FS-8002 injection
Q3W or until the patient develops PD, intolerable toxicity, death, loss of follow-up, voluntary withdrawal, or the end of the study, whichever occurs first
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Affiliated Hospital of China Medical University, Shenyang
RECRUITING
Harbin Medical University Cancer Hospital, Heilongjiang
RECRUITING
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute,Shandong Cancer Hospital), Shandong
NOT_YET_RECRUITING
The First Affiliated Hospital of Zhejiang Medical University, Zhejiang
RECRUITING
Fujian Cancer hospital, Fujian
RECRUITING
Union Hospital, Tongji Medical College, Hubei
RECRUITING
Hubei Cancer Hospital, Hubei
RECRUITING
Meizhou People's Hospital, Guangdong
RECRUITING
Hebei General Hospital, Hebei
Shanghai Pushi Medical Science Co. Ltd
INDUSTRY